EZMEKLY Hard capsule Ref.[115576] Active ingredients: Mirdametinib

Source: European Medicines Agency (EU)  Revision Year: 2025  Publisher: SpringWorks Therapeutics Ireland Limited, Hamilton House, 28 Fitzwilliam Place, Dublin 2, D02 P283, Ireland

Product name and form

Ezmekly 1 mg hard capsules.

Ezmekly 2 mg hard capsules.

Pharmaceutical Form

Hard capsule (capsule).

Ezmekly 1 mg hard capsules: Size 3 (approximately 16 mm × 6 mm) capsule comprised of a light green opaque body and cap with 'MIR 1 mg' printed in white ink on the cap.

Ezmekly 2 mg hard capsules: Size 1 (approximately 19 mm × 7 mm) capsule comprised of a white opaque body and a blue‑green opaque cap with 'MIR 2 mg' printed in white ink on the cap.

Qualitative and quantitative composition

Ezmekly 1 mg hard capsules: Each hard capsule contains 1 mg of mirdametinib.

Ezmekly 2 mg hard capsules: Each hard capsule contains 2 mg of mirdametinib.

For the full list of excipients, see section 6.1.

Active Ingredient

Mirdametinib is a selective, non‑competitive inhibitor of mitogen‑activated protein kinase kinases 1 and 2 (MEK1/2). Mirdametinib blocks MEK activity and the rat sarcoma (RAS)‑rapidly accelerated fibrosarcoma (RAF)‑MEK pathway. Therefore, MEK inhibition blocks proliferation and survival of tumour cells in which the RAF‑MEK‑extracellular related kinase (ERK) pathway is activated.

List of Excipients

Capsule content:

Microcrystalline cellulose (E460)
Croscarmellose sodium (E468)
Magnesium stearate (E572)

Capsule shell:

Gelatin (E441)
Titanium dioxide (E171)
Yellow iron oxide (E172)
Brilliant blue (E133)

Printing ink:

Potassium hydroxide (E525)
Propylene glycol (E1520)
Purified water
Shellac (E904)
Titanium dioxide (E171)

Pack sizes and marketing

High‑density polyethylene (HDPE) bottle, secured with child‑resistant closure and aluminium foil induction seal.

1 mg hard capsules are provided in a carton containing one bottle of 42 capsules.

2 mg hard capsules are provided in a carton containing one bottle of 42 or 84 capsules.

Not all pack sizes may be marketed.

Marketing authorization holder

SpringWorks Therapeutics Ireland Limited, Hamilton House, 28 Fitzwilliam Place, Dublin 2, D02 P283, Ireland

Marketing authorization dates and numbers

EU/1/25/1950/003
EU/1/25/1950/004
EU/1/25/1950/005

Date of first authorisation: 17 July 2025

Drugs

Drug Countries
EZMEKLY Austria, Estonia, Italy, Lithuania, Romania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.